ATRO Medical

Global front-runner in meniscus prostheses
Despite the vast number of patients suffering from post- meniscectomy pain syndrome, there is no effective treatment for many of them. ATRO Medical is the global front-runner in developing a solution—the Artimis^® Meniscus Prostheses, an anatomically shaped polymer prosthesis to replace the damaged meniscus of patients and contribute to the preservation of the knee joint. The company aims to bring relief and restore mobility to patients who struggle with one of the leading causes of disability in Europe and the US.

From idea to trial
As a driven sports practitioner, Doctor Tony van Tienen chose to specialize in orthopedics and has built deep expertise in sports-related knee injuries since. He has been working on meniscus prostheses for twenty-five years. In 2010, he joined the BioMedical Materials collaboration between clinical, biomechanical, and polymer experts where his team developed the Trammpolin^® Meniscus Prosthesis, now called Artimis^®. In 2016, ATRO Medical was founded as a spin-off from the Radboud University Medical Center and DSM and has since completed their second clinical trial thanks to the investment of 819 Capital Partners, Thuja Capital Management, Oost NL, and the Brabantse Ontwikkelingsmaatschappij. The company has its offices in Nijmegen and Uden and has a service agreement with the Radboud Medical Center for its technology platform.

The next phase: funding and US market access
ATRO Medical is in full expansion with a focus on the US market. Granted with the FDA Breakthrough Device Designation, the company is in pole position to bring the Artimis^® Meniscus Prostheses to US patients as the designation ensures a predictable and timely assessment and priority in upcoming FDA reviews. ATRO Medical is acquiring the necessary funding and strategic partnerships with orthopedic device companies to set up the upcoming regulatory studies for success and provide countless patients with relief and restored mobility.